BOOK YOUR APPOINTMENT WITH DR DAN REARDON
MB ChB • BSc Anatomy • MSc Mental Health
A&E Doctor • Founder • Medical Advisor
DEPRESCRIBING CLINIC
Flagship: GLP-1 Exit Strategy
Clinician-led medication review and deprescribing where appropriate, paired with lifestyle medicine and performance-grade systems for long-term maintenance.
Medical supervision • Strength-first • Data-led • No gimmicks
As seen / spoken at:
NBC The Doctors
|
Buzzfeed
|
Health 2.0
|
Upgrade Labs
|
Bulletproof
|
GCN
|
NBC The Doctors | Buzzfeed | Health 2.0 | Upgrade Labs | Bulletproof | GCN |
Selected appearances and talks across health, performance, and technology.
DEPRESCRIBING — WITH A PLAN FOR WHAT HAPPENS NEXT
Coming off medication isn’t the hard part. Staying stable afterwards is. This clinic is built for the rebound points—appetite return, symptoms, sleep disruption, anxiety spikes, reflux flare-ups, and the slow drift back to baseline.
Medical Review
Clarify indication, current benefit, and risk
Identify interactions and “medication load”
Shared decision-making, not ideology
Deprescribing Strategy
Step-down planning where appropriate
Symptom monitoring and contingency rules
Coordination with your GP/specialist when needed
Lifestyle & Performance Rebuild
Strength-first body composition strategy
Appetite/satiety structure and food environment design
Sleep, stress physiology, and long-term maintenance systems
DEPRESCRIBING PATHWAYS
Each pathway has its own rebound risks. Plans are individual and may involve continuing, reducing, switching, or stopping—depending on your physiology, history, and goals.
GLP-1 Exit Strategy (Flagship)
For people preparing to taper/stop GLP-1s and keep results through appetite return and maintenance.
SSRI / Antidepressant Review (e.g. sertraline)
Careful taper planning and stability scaffolding (sleep, stress load, relapse prevention).
Statin Review (where appropriate)
Risk stratification and shared decision-making to confirm whether ongoing therapy remains indicated.
PPI Review
(reflux medications)
Rebound reflux planning, triggers, step-down strategies, and lifestyle levers.
Medication Load Review (Polypharmacy)
For people on multiple meds who want a coherent, clinician-led plan.
HOW IT WORKS
A five-step clinical process built for long-term maintenance.
Assess → Stabilise → Plan → Taper / Adjust → Maintain
-
We review your history, goals, current medication list, and previous attempts. We map the likely rebound points and decide what success needs to look like for you.
-
Before changing anything, we build a stable baseline: nutrition structure, strength plan, sleep anchors, and symptom tracking. This reduces noise and improves decision-making.
-
You get a personalised plan based on risk/benefit: what to continue, what to adjust, and what may be reduced (where appropriate). Clear monitoring targets and check-in points.
-
Step-down is gradual and responsive, with symptom tracking and decision rules. We go slower if needed and coordinate with your GP/specialist where appropriate.
-
We lock in maintenance: habits, environment design, relapse prevention, and follow-up. The goal is stability without white-knuckling.
Medication changes are always individual and should never be done abruptly.
WHY DR DAN
A doctor who understands performance — and reality.
I continue to work in the NHS A&E and privately specialise in the gap between intention and reality—building systems that make change stick. My background spans clinical medicine, sports performance, education, and health technology, translating physiology into outcomes you can repeat.
NHS A&E doctor — frontline clinical reality
Founder + medical advisor — systems, strategy, outcomes
Public educator — media, podcasts, international speaking
Deprescribing is a phase of medicine — not a moment.
WHO IS THIS FOR
If any of these are you…
On a GLP-1 — and you’re thinking: I can’t stay on this forever.
Rebound symptoms — reflux, anxiety shifts, sleep disruption, fatigue.
Stopped already — appetite is back, weight is trending up.
Multiple medications — you want one coherent plan.
Clinically responsible deprescribing — evidence-led, not trend-driven.
Maintenance systems — strength, muscle, stability (not extremes).
Start with a Deprescribing Assessment.
FAQ
Short answers to the most common questions.
-
No. We review indication and risk/benefit. Sometimes the right answer is to continue, adjust, or deprescribe—case by case.
-
Yes, where appropriate. Some plans work best in shared care.
-
No. Many medications require gradual tapering and monitoring. Never stop abruptly without clinical advice.
-
GLP-1 exit is the flagship pathway, but the clinic covers multiple deprescribing pathways.